OMGA
vs
S&P 500
OMGA
S&P 500
Over the past 12 months, OMGA has underperformed S&P 500, delivering a return of -94% compared to the S&P 500's +14% growth.
Stocks Performance
OMGA vs S&P 500
Performance Gap
OMGA vs S&P 500
Performance By Year
OMGA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Omega Therapeutics Inc
Glance View
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-07-30. The firm is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. The company has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.
